Home > Haematology > ASH 2020 > Multiple Myeloma > Melflufen well tolerated with encouraging activity in heavily pretreated R/R MM

Melflufen well tolerated with encouraging activity in heavily pretreated R/R MM

Presented By
Dr Enrique Ocio, University Hospital Marqués de Valdecilla, Spain

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2020
Trial
Phase 1/2, ANCHOR (OP-104)
In heavily pretreated patients with relapsed/refractory multiple myeloma (R/R MM) who were refractory to an immunomodulatory drug and/or a proteasome inhibitor and had poor prognostic factors, melflufen plus dexamethasone as a triplet regimen with either daratumumab or bortezomib was well tolerated. Both combinations demonstrated encouraging activity [1]. Patients with R/R MM often develop resistance to standard treatments, underscoring the need for novel therapies with new mechanisms of action. Melphalan flufenamide (melflufen) is an investigational first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly releases alkylating agents into tumour cells. In the phase 2 HORIZON study (OP-106; NCT02963493), the activity of melflufen plus dexamethasone was demonstrated in heavily pretreated R/R MM patients refractory to pomalidomide and/or anti-CD38...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on